Clinical Takeaway
In this small pilot trial of 20 adults with diagnosed insomnia disorder, a single oral dose of 10 mg THC combined with 200 mg CBD reduced total sleep time compared to placebo, suggesting that this cannabinoid combination did not improve objective sleep in this population. High-density EEG findings indicated measurable changes in sleep architecture, and next-day alertness was also affected, underscoring that cannabinoid sleep aids carry real physiological consequences beyond subjective experience. Patients and clinicians should interpret consumer claims about cannabis as a sleep aid cautiously, as controlled evidence does not yet support routine use for insomnia.
#8 Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.
Citation: Suraev Anastasia et al.. Acute Effects of Oral Cannabinoids on Sleep and High-Density EEG in Insomnia: A Pilot Randomised Controlled Trial.. Journal of sleep research. 2026. PMID: 40631525.
Design: 5 Journal: 0 N: 0 Recency: 3 Pop: 2 Human: 1 Risk: 0
This pilot study provides the first high-resolution electrophysiologic characterization of THC/CBD effects on sleep architecture in clinically diagnosed insomnia, addressing a significant gap between widespread patient use and limited objective neurophysiologic data. The high-density EEG methodology enables detection of subtle alterations in sleep stage progression and cortical activity that standard polysomnography cannot capture, potentially clarifying whether cannabinoid-induced sleep improvements reflect genuine architecture normalization or masking of underlying sleep disruption. These findings are essential for evidence-based clinical decision-making regarding cannabinoid prescription for insomnia, particularly given the lack of robust efficacy and safety data in this population.
Methodological Considerations:
- Self-reported outcomes — recall and social-desirability bias risk
Abstract: Cannabinoids, particularly Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD), have gained popularity as alternative sleep aids; however, their effects on sleep architecture and next-day function remain poorly understood. Here, in a pilot trial, we examined the effects of a single oral dose containing 10 mg THC and 200 mg CBD (THC/CBD) on objective sleep outcomes and next-day alertness using 256-channel high-density EEG in 20 patients with DSM-5 diagnosed insomnia disorder (16 female; mean (SD) age, 46.1 (8.6) years). We showed that THC/CBD decreased total sleep time (-24.5 min, p = 0.05, d = -0.5) with no change in wake after sleep onset (+10.7 min, p > 0.05) compared to placebo. THC/CBD also significantly decreased time spent in REM sleep (-33.9 min, p < 0.001, d = -1.5) and increased latency to REM sleep (+65.6 min, p = 0.008, d = 0.7). High-density EEG analysis revealed regional decreases in gamma activity during N2 sleep, and in delta activity during N3 sleep, and a regional increase in beta and alpha activity during REM sleep. While there was no observed change in next-day objective alertness, a small but significant increase in self-reported sleepiness was noted with THC/CBD (+0.42 points, p = 0.02, d = 0.22). No changes in subjective sleep quality, cognitive performance, or simulated driving performance were observed. These findings suggest that a single dose of cannabinoids, particularly THC, may acutely influence sleep, primarily by suppressing REM sleep, without noticeable next-day impairment (≥ 9 h post-treatment). Australian New Zealand Clinical Trial Registry (ACTRN12619000714189) https://www.anzctr.org.au/.
😴 This pilot study provides early objective data suggesting that a single dose of combined THC/CBD may influence sleep architecture in insomnia patients, though the small sample size (n=20), predominance of female participants, and single-dose design substantially limit generalizability and preclude firm conclusions about efficacy or safety profiles. The use of high-density EEG offers mechanistic insight beyond subjective sleep reporting, but we lack critical information about next-day cognitive or psychomotor effects, tolerance development with repeated dosing, and how results might differ across age groups, comorbidities, or concurrent medications commonly seen in insomnia populations. Important confounders including baseline cannabinoid exposure, prior sleep medication use, and individual pharmacokinetic variation are not fully characterized, and the relatively high CBD-to-THC ratio employed here may not reflect typical patient preferences or available formulations. While this work is a valuable proof-of-concept, clinicians should remain cautious about recommending cannabinoids for insomnia outside of research